Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

BMS' Cobenfy Shows Steady Growth in Schizophrenia Market, Eyes Expansion

Bristol Myers Squibb's (BMS) novel schizophrenia medication, Cobenfy, has completed its first year on the market, demonstrating steady growth while facing challenges in a highly entrenched treatment landscape. The company is now focusing on expanding the drug's reach and exploring new indications to fulfill its potential as a blockbuster therapy.

NoahAI News10/31/2025

Zimmer Biomet Secures FDA Breakthrough Status for Innovative Iodine-Treated Hip Implant

Zimmer Biomet, a leading medical device company, has achieved a significant milestone in its quest to reduce post-operative infections in joint replacement surgeries. The company recently announced that it has received breakthrough device status from the U.S. Food and Drug Administration (FDA) for its iodine-treated total hip replacement system.

NoahAI News10/31/2025

Medline Files for Initial Public Offering, Aims to Raise $5 Billion

Medical and surgical products provider Medline has filed for an initial public offering (IPO) in the United States, potentially raising $5 billion at a $50 billion valuation. The move comes as the company reports strong growth and outlines ambitious expansion plans.

NoahAI News10/31/2025

For-Profit Hospitals See Revenue Surge Driven by Medicaid Supplemental Payments

Major for-profit hospital systems in the United States have reported substantial revenue increases in their third-quarter earnings, largely attributed to Medicaid supplemental payments. This unexpected boost has led to revised forecasts and renewed focus on high-acuity services and market expansions.

NoahAI News10/31/2025

Sensei Biotherapeutics Discontinues Cancer Drug Program, Announces Restructuring

Sensei Biotherapeutics, a clinical-stage biotechnology company, has announced the discontinuation of its sole clinical-stage cancer drug program and plans for significant restructuring, including layoffs, to conserve its remaining cash reserves.Sensei has decided to wind down the phase 1/2 clinical trial of solnerstotug, its anti-VISTA monoclonal antibody. This decision comes just two weeks after the company reported promising data from the trial, which showed a six-month progression-free survival rate of 50% in the 15-mg/kg cohort for patients with "hot" tumor types.

NoahAI News10/31/2025

Summa Health CEO to Step Down Following General Catalyst Acquisition

Summa Health, a major healthcare provider in Ohio, is set to undergo significant leadership changes following its recent acquisition by venture capital firm General Catalyst. Dr. Cliff Deveny, the current CEO and President of Summa Health, has announced his intention to step down from his position at the end of 2025, less than two months after the completion of the landmark $515 million acquisition deal.

NoahAI News10/31/2025

Lilly's Zepbound and Mounjaro Dominate Q3, Surpassing Expectations Despite Formulary Challenges

Eli Lilly's obesity and diabetes medications, Zepbound and Mounjaro, have continued their meteoric rise in the pharmaceutical market, delivering a combined $10.1 billion in global sales for the third quarter of 2025. This impressive performance comes despite challenges in formulary listings and showcases the growing dominance of Lilly's incretin franchise in the metabolic disease space.

NoahAI News10/31/2025

Takeda Discontinues Multiple Programs in Strategic Pipeline Shift

Takeda Pharmaceutical Company has announced significant changes to its drug development pipeline, including the termination of several programs across different therapeutic areas. These decisions, revealed in the company's third-quarter earnings report, reflect a strategic realignment of Takeda's research and development efforts.

NoahAI News10/31/2025

Cigna Reports Strong Q3 Results, Reaffirms 2025 Outlook Amid PBM Business Pressures

The Cigna Group has announced robust financial results for the third quarter of 2025, posting a significant increase in profit and beating Wall Street expectations. The health services company reaffirmed its full-year outlook while navigating challenges in its pharmacy benefit management (PBM) business.

NoahAI News10/31/2025

CSL Seqirus Inks Flu Vaccine Deal with Saudi Arabia, Delays Spinoff Plans

CSL Seqirus, the vaccine unit of Australian biotech CSL, has entered into a significant agreement with Saudi Arabia to supply cell-based influenza vaccines and establish local production capabilities. This development comes as the company simultaneously announces a delay in its previously planned spinoff, citing market volatility in the U.S. influenza vaccine sector.

NoahAI News10/31/2025

AI Integration in Healthcare: Suki and WellSky Partner to Enhance EHR Capabilities

Health technology company WellSky has announced a strategic partnership with Suki to integrate ambient artificial intelligence (AI) capabilities into its specialty care electronic health record (EHR) system. This collaboration marks a significant step forward in the application of AI technologies within the healthcare sector, particularly in post-acute care settings.

NoahAI News10/31/2025

Biopharma Professionals Contemplate Exodus Amid Industry Challenges

In a striking revelation, nearly one-third of biotech and pharmaceutical professionals are considering leaving the United States to pursue career opportunities abroad, according to recent findings from BioSpace. This trend reflects growing concerns about the current state of the biopharma industry in the U.S. and highlights the complex challenges facing the sector.

NoahAI News10/31/2025

«1...3 4 5...67 »